Phio Pharmaceuticals Corp. (PHIO) 股票分析

公司概述

Phio Pharmaceuticals Corp. operates as a clinical stage biopharmaceutical entity focused on the development of immuno-oncology therapeutics within the United States market. The company functions within the Healthcare sector and specifically targets the Biotechnology industry, a domain characterized by high R&D expenditure and significant regulatory scrutiny for novel drug candidates. Phio currently maintains a market capitalization of $14.64M and employs a workforce of 6 individuals, indicating an extremely lean operational structure typical of early-stage development firms. These valuation metrics suggest that the company is in a pre-revenue or very early revenue generation phase, where value is derived primarily from intellectual property and clinical trial progress rather than established sales volumes, placing it in a high-risk, high-potential developmental stage relative to mature peers.

财务健康

The company reports a Net Income of $-8,698,000 over the trailing twelve months, while Revenue and EBITDA figures are listed as N/A, indicating that the business is currently operating without established commercial sales or measurable profitability from operations. The absence of reported revenue combined with a negative net income reveals a cost structure entirely dependent on research and development expenditures and operational overhead rather than product sales. Phio reports Free Cash Flow of $-5,056,500, which signifies a substantial cash burn rate that necessitates continuous capital raising to sustain clinical trial activities and general corporate operations. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, reflecting the standard financial presentation for pre-revenue biotechnology companies that have not yet generated taxable sales. The balance sheet displays a Cash position of $21.03M contrasted against $0 in Debt, creating a leverage-free financial profile that provides maximum flexibility for funding expensive clinical programs. With a Current Ratio of 16.03, the company possesses exceptional short-term liquidity, holding significantly more current assets than current liabilities to cover immediate obligations. The Return on Equity stands at -69.9% and Return on Assets at -42.3%, metrics that demonstrate the dilutive impact of the company's operating expenses on shareholder and asset value during this developmental phase.

估值评估

The valuation metrics for Phio show a Trailing P/E Ratio of N/A due to lack of earnings, while the Forward P/E is listed as -2.03, a figure that technically implies negative expected earnings in the forward model. The Price to Book ratio is 0.73, indicating that the market values the company's equity at a discount relative to its book value, a common characteristic for speculative biotech assets with limited tangible assets. The Price to Sales ratio is N/A and the EV/EBITDA is 0.69, suggesting that traditional sales-based or earnings-based multiples are not applicable for standard comparison, and the low EV/EBITDA reflects the company's negative earnings multiple. The stock has traded between a 52-Week High of $4.19 and a 52-Week Low of $0.81, illustrating a wide trading range driven by volatility in clinical trial outcomes and market sentiment. The Beta value is 0.91, which indicates that the stock's price volatility is roughly in line with the broader market, despite the high inherent risk associated with its clinical-stage business model.

Growth & Income

Phio Pharmaceuticals reports N/A for both Revenue Growth (YoY) and Earnings Growth (YoY), as the company has not yet generated sufficient sales data to calculate year-over-year growth rates. Consequently, there is no dividend yield or payout ratio available for this entity, as the company reinvests all available capital into advancing its immuno-oncology pipeline rather than distributing income to shareholders. The lack of a dividend program and the zero payout ratio are standard for clinical stage biotechs that must prioritize funding Phase 1b dose-escalating trials for compounds like PH-762 and PH-894 over shareholder returns. The overall growth and income profile is characterized by a complete reliance on external capital markets to fund future development, with no current income generation or historical growth trajectory to analyze.